Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake ...

Study links GLP-1 diabetes drugs like Novo's Ozempic and Eli Lilly's Mounjaro to 12% lower Alzheimer's risk, ahead of Novo's ...

One of Inhibrx Biosciences’ antibody candidates has shown encouraging early efficacy in colorectal cancer. But its safety is ...

J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...

ArriVent BioPharma, led by Bing Yao, licenses ADC MRG007 from Lepu Biopharma for $47M upfront, adding the drug to a portfolio ...

Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some ...

A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in ...

J&J’s Spravato nasal spray received a label expansion on Tuesday, now approved as a standalone treatment for major depressive ...

The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health ...

A father-and-son biotech with ties to Iceland and Philadelphia has put together a €26.5 million Series A to develop oral ...

Ascentage Pharma seeks $133M via US listing, markets olverembatinib in China with Takeda holding global rights. CEO Dajun ...

UnitedHealth's OptumRx to pass 100% of drug rebates to clients by 2028, but critics say GPO structure may still hide true ...